Cellebrite DI (NASDAQ:CLBT) Rating Increased to Buy at Wall Street Zen

Key Points

• Cellebrite DI has been upgraded to a "buy" rating by Wall Street Zen, indicating increasing confidence in the company's stock.
• The stock is currently trading at $18.63 with a market cap of $4.46 billion, reflecting a notable rise from a 1-year low of $13.10.
• The company reported $0.12 EPS for the last quarter, surpassing estimates, and its revenue increased by 18.4% year-over-year.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Friday.

Other analysts also recently issued reports about the stock. Lake Street Capital dropped their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and an average price target of $21.75.

Cellebrite DI Stock Performance

CLBT stock traded up $0.33 during mid-day trading on Friday, hitting $18.63. 1,150,340 shares of the company were exchanged, compared to its average volume of 1,870,179. The firm has a market cap of $4.46 billion, a P/E ratio of -24.51, a P/E/G ratio of 3.33 and a beta of 1.28. The firm's 50 day simple moving average is $15.81 and its 200 day simple moving average is $16.96. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Cellebrite DI by 32.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 148,132 shares of the company's stock worth $3,263,000 after purchasing an additional 36,341 shares during the period. Mackenzie Financial Corp bought a new position in Cellebrite DI during the fourth quarter worth $776,000. California State Teachers Retirement System boosted its position in Cellebrite DI by 19.3% during the fourth quarter. California State Teachers Retirement System now owns 71,385 shares of the company's stock worth $1,573,000 after purchasing an additional 11,555 shares during the period. SG Americas Securities LLC boosted its position in Cellebrite DI by 46.2% during the first quarter. SG Americas Securities LLC now owns 306,287 shares of the company's stock worth $5,951,000 after purchasing an additional 96,758 shares during the period. Finally, Handelsbanken Fonder AB boosted its position in Cellebrite DI by 749.9% during the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after purchasing an additional 1,340,000 shares during the period. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.